Abstract
The utility of comprehensive genomic profiling in selection of actionable targeted therapy in recurrent or refractory epithelial ovarian, fallopian tube and peritoneal carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have